• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

利用 Cas9 对基因组编辑 T 细胞的微流控涡旋脱落进行数值优化。

Numerical optimization of microfluidic vortex shedding for genome editing T cells with Cas9.

机构信息

Indee Labs, Berkeley, CA, USA.

Future Industries Institute, University of South Australia, Mawson Lakes, SA, Australia.

出版信息

Sci Rep. 2021 Jun 3;11(1):11818. doi: 10.1038/s41598-021-91307-y.

DOI:10.1038/s41598-021-91307-y
PMID:34083685
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8175688/
Abstract

Microfluidic vortex shedding (µVS) can rapidly deliver mRNA to T cells with high yield and minimal perturbation of the cell state. The mechanistic underpinning of µVS intracellular delivery remains undefined and µVS-Cas9 genome editing requires further studies. Herein, we evaluated a series of µVS devices containing splitter plates to attenuate vortex shedding and understand the contribution of computed force and frequency on efficiency and viability. We then selected a µVS design to knockout the expression of the endogenous T cell receptor in primary human T cells via delivery of Cas9 ribonucleoprotein (RNP) with and without brief exposure to an electric field (eµVS). µVS alone resulted in an equivalent yield of genome-edited T cells relative to electroporation with improved cell quality. A 1.8-fold increase in editing efficiency was demonstrated with eµVS with negligible impact on cell viability. Herein, we demonstrate efficient processing of 5 × 10 cells suspend in 100 µl of cGMP OptiMEM in under 5 s, with the capacity of a single device to process between 10 to 10 in 1 to 30 s. Cumulatively, these results demonstrate the rapid and robust utility of µVS and eµVS for genome editing human primary T cells with Cas9 RNPs.

摘要

微流控涡旋脱落(µVS)可以快速将 mRNA 递送至 T 细胞,具有高产率和对细胞状态的最小干扰。µVS 细胞内递送的机制基础仍未定义,µVS-Cas9 基因组编辑需要进一步研究。在此,我们评估了一系列包含分流板的 µVS 装置以减弱涡旋脱落,并了解计算力和频率对效率和活力的贡献。然后,我们选择了一种 µVS 设计,通过递送 Cas9 核糖核蛋白(RNP)并用和不用短暂暴露于电场(eµVS)来敲除原代人 T 细胞中的内源性 T 细胞受体表达。µVS 单独处理与电穿孔相比,产生了等效产量的基因组编辑 T 细胞,且细胞质量得到改善。用 eµVS 可将编辑效率提高 1.8 倍,而对细胞活力的影响可以忽略不计。在此,我们证明了在不到 5 秒的时间内,在 500µl 的 cGMP OptiMEM 中有效处理 5×10 个细胞,单个装置的处理能力在 1 到 30 秒之间可以处理 10 到 10 个细胞。总之,这些结果证明了 µVS 和 eµVS 在使用 Cas9 RNP 对人类原代 T 细胞进行基因组编辑方面的快速和强大的应用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/edf7/8175688/1c61aab38540/41598_2021_91307_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/edf7/8175688/218415ff7826/41598_2021_91307_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/edf7/8175688/35b1f67f23b5/41598_2021_91307_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/edf7/8175688/e81dca1f3b7a/41598_2021_91307_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/edf7/8175688/61d93d633e46/41598_2021_91307_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/edf7/8175688/8196132a7350/41598_2021_91307_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/edf7/8175688/1c61aab38540/41598_2021_91307_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/edf7/8175688/218415ff7826/41598_2021_91307_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/edf7/8175688/35b1f67f23b5/41598_2021_91307_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/edf7/8175688/e81dca1f3b7a/41598_2021_91307_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/edf7/8175688/61d93d633e46/41598_2021_91307_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/edf7/8175688/8196132a7350/41598_2021_91307_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/edf7/8175688/1c61aab38540/41598_2021_91307_Fig6_HTML.jpg

相似文献

1
Numerical optimization of microfluidic vortex shedding for genome editing T cells with Cas9.利用 Cas9 对基因组编辑 T 细胞的微流控涡旋脱落进行数值优化。
Sci Rep. 2021 Jun 3;11(1):11818. doi: 10.1038/s41598-021-91307-y.
2
Strategies in the delivery of Cas9 ribonucleoprotein for CRISPR/Cas9 genome editing.用于 CRISPR/Cas9 基因组编辑的 Cas9 核糖核蛋白递送策略。
Theranostics. 2021 Jan 1;11(2):614-648. doi: 10.7150/thno.47007. eCollection 2021.
3
High-throughput continuous-flow microfluidic electroporation of mRNA into primary human T cells for applications in cellular therapy manufacturing.高通量连续流微流控电穿孔将 mRNA 导入原代人 T 细胞,用于细胞治疗产品制造。
Sci Rep. 2020 Oct 22;10(1):18045. doi: 10.1038/s41598-020-73755-0.
4
High content analysis platform for optimization of lipid mediated CRISPR-Cas9 delivery strategies in human cells.用于优化脂质介导的CRISPR-Cas9在人类细胞中递送策略的高内涵分析平台。
Acta Biomater. 2016 Apr 1;34:143-158. doi: 10.1016/j.actbio.2015.12.036. Epub 2015 Dec 30.
5
Comparative analysis of lipid Nanoparticle-Mediated delivery of CRISPR-Cas9 RNP versus mRNA/sgRNA for gene editing in vitro and in vivo.脂质纳米颗粒介导的 CRISPR-Cas9 RNP 与 mRNA/sgRNA 递送至体内外基因编辑的比较分析。
Eur J Pharm Biopharm. 2024 Mar;196:114207. doi: 10.1016/j.ejpb.2024.114207. Epub 2024 Feb 6.
6
Optimized RNP transfection for highly efficient CRISPR/Cas9-mediated gene knockout in primary T cells.优化的 RNP 转染用于高效的 CRISPR/Cas9 介导的原代 T 细胞基因敲除。
J Exp Med. 2018 Mar 5;215(3):985-997. doi: 10.1084/jem.20171626. Epub 2018 Feb 7.
7
Simple in Vivo Gene Editing via Direct Self-Assembly of Cas9 Ribonucleoprotein Complexes for Cancer Treatment.通过 Cas9 核糖核蛋白复合物的直接自组装进行简单的体内基因编辑用于癌症治疗。
ACS Nano. 2018 Aug 28;12(8):7750-7760. doi: 10.1021/acsnano.8b01670. Epub 2018 Jul 26.
8
Optimization of CRISPR/Cas9 Delivery to Human Hematopoietic Stem and Progenitor Cells for Therapeutic Genomic Rearrangements.优化 CRISPR/Cas9 递送至人类造血干/祖细胞用于治疗性基因组重排。
Mol Ther. 2019 Jan 2;27(1):137-150. doi: 10.1016/j.ymthe.2018.10.008. Epub 2018 Oct 17.
9
Intracellular delivery of mRNA to human primary T cells with microfluidic vortex shedding.微流控涡旋剪切实现 mRNA 向人原代 T 细胞的胞内递送。
Sci Rep. 2019 Mar 1;9(1):3214. doi: 10.1038/s41598-019-40147-y.
10
Development of a microfluidic cell transfection device into gene-edited CAR T cell manufacturing workflow.开发一种微流控细胞转染装置,将其纳入基因编辑 CAR T 细胞制造工作流程中。
Lab Chip. 2023 Nov 7;23(22):4804-4820. doi: 10.1039/d3lc00311f.

引用本文的文献

1
Microfluidic Platforms for Ex Vivo and In Vivo Gene Therapy.用于体外和体内基因治疗的微流控平台
Biosensors (Basel). 2025 Aug 4;15(8):504. doi: 10.3390/bios15080504.
2
Scalable intracellular delivery via microfluidic vortex shedding enhances the function of chimeric antigen receptor T-cells.通过微流体涡旋脱落实现的可扩展细胞内递送增强了嵌合抗原受体T细胞的功能。
Sci Rep. 2025 Feb 17;15(1):5749. doi: 10.1038/s41598-025-89070-5.
3
Scalable intracellular delivery via microfluidic vortex shedding enhances the function of chimeric antigen receptor T-cells.

本文引用的文献

1
Tregs and Mixed Chimerism as Approaches for Tolerance Induction in Islet Transplantation.调节性T细胞与混合嵌合体作为胰岛移植诱导免疫耐受的方法
Front Immunol. 2021 Jan 29;11:612737. doi: 10.3389/fimmu.2020.612737. eCollection 2020.
2
High-throughput continuous-flow microfluidic electroporation of mRNA into primary human T cells for applications in cellular therapy manufacturing.高通量连续流微流控电穿孔将 mRNA 导入原代人 T 细胞,用于细胞治疗产品制造。
Sci Rep. 2020 Oct 22;10(1):18045. doi: 10.1038/s41598-020-73755-0.
3
A review of emerging physical transfection methods for CRISPR/Cas9-mediated gene editing.
通过微流体涡旋脱落实现的可扩展细胞内递送增强了嵌合抗原受体T细胞的功能。
Res Sq. 2024 Sep 19:rs.3.rs-4870379. doi: 10.21203/rs.3.rs-4870379/v1.
4
Scalable intracellular delivery via microfluidic vortex shedding enhances the function of chimeric antigen receptor T-cells.通过微流体涡旋脱落实现的可扩展细胞内递送增强了嵌合抗原受体T细胞的功能。
bioRxiv. 2024 Jul 13:2024.06.25.600671. doi: 10.1101/2024.06.25.600671.
5
High throughput intracellular delivery by viscoelastic mechanoporation.高通量细胞内递呈的粘弹性机械穿孔法。
Nat Commun. 2024 Jan 2;15(1):115. doi: 10.1038/s41467-023-44447-w.
6
A high-throughput microfluidic mechanoporation platform to enable intracellular delivery of cyclic peptides in cell-based assays.一种用于在基于细胞的分析中实现环肽细胞内递送的高通量微流控机械穿孔平台。
Bioeng Transl Med. 2023 May 13;8(5):e10542. doi: 10.1002/btm2.10542. eCollection 2023 Sep.
7
Protocol for assessment of the efficiency of CRISPR/Cas RNP delivery to different types of target cells.CRISPR/Cas RNP 递送至不同类型靶细胞效率评估的方案。
PLoS One. 2021 Nov 9;16(11):e0259812. doi: 10.1371/journal.pone.0259812. eCollection 2021.
CRISPR/Cas9 介导的基因编辑新兴物理转染方法综述。
Theranostics. 2020 Apr 15;10(12):5532-5549. doi: 10.7150/thno.43465. eCollection 2020.
4
Memory T cells: strategies for optimizing tumor immunotherapy.记忆 T 细胞:优化肿瘤免疫治疗的策略。
Protein Cell. 2020 Aug;11(8):549-564. doi: 10.1007/s13238-020-00707-9. Epub 2020 Mar 27.
5
PD-1: A Driver or Passenger of T Cell Exhaustion?PD-1:T 细胞耗竭的驱动者还是乘客?
Mol Cell. 2020 Mar 5;77(5):930-931. doi: 10.1016/j.molcel.2020.02.013.
6
CRISPR-engineered T cells in patients with refractory cancer.经 CRISPR 基因编辑的 T 细胞治疗难治性癌症的患者。
Science. 2020 Feb 28;367(6481). doi: 10.1126/science.aba7365. Epub 2020 Feb 6.
7
Next-generation regulatory T cell therapy.下一代调节性 T 细胞治疗。
Nat Rev Drug Discov. 2019 Oct;18(10):749-769. doi: 10.1038/s41573-019-0041-4. Epub 2019 Sep 20.
8
Intracellular delivery of mRNA to human primary T cells with microfluidic vortex shedding.微流控涡旋剪切实现 mRNA 向人原代 T 细胞的胞内递送。
Sci Rep. 2019 Mar 1;9(1):3214. doi: 10.1038/s41598-019-40147-y.
9
Cell engineering with microfluidic squeezing preserves functionality of primary immune cells in vivo.微流控挤压的细胞工程可在体内保持原代免疫细胞的功能。
Proc Natl Acad Sci U S A. 2018 Nov 13;115(46):E10907-E10914. doi: 10.1073/pnas.1809671115. Epub 2018 Oct 31.
10
Reducing Culture Improves the Antileukemic Activity of Chimeric Antigen Receptor (CAR) T Cells.降低细胞培养条件可提高嵌合抗原受体(CAR)T 细胞的抗白血病活性。
Cancer Immunol Res. 2018 Sep;6(9):1100-1109. doi: 10.1158/2326-6066.CIR-17-0405. Epub 2018 Jul 20.